Research progress of Chinese and western medicine intervention on platelet transfusion refractoriness in patients with liver cancer
NONG Yaobin1 HUANG Hongna2 HUANG Jingjing3 DONG Zhixin4 SONG Wenxuan1 XIAO Xiyu1 DU Yuanqin1
1.Graduate School, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530022, China;
2.Teaching and Research Section of Internal Medicine of Chinese Medicine, the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530022, China;
3.Department of Lienal, Gastric, and Hepatic Disease, Xianhu Branch of the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530022, China;
4.Ward Two, Department of Oncology, Xianhu Branch of the First Affiliated Hospital of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530022, China
Abstract：The occurrence of liver cancer is often evolved from the progression of viral hepatitis, cirrhosis, aflatoxin contamination, and so on. Most patients with liver cancer are complicated with hyperplenism, which leads to the reduction of their platelets in peripheral blood to varying degrees. At the same time, targeted drug therapy can produce strong inhibition on megakaryocytes and bone marrow function, and can also lead to a decrease in the number of platelets. In the treatment of platelet transfusion in patients with liver cancer, there may be several times of infusion but the ideal effect can not be achieved, the bleeding status is not alleviated, and even platelet transfusion refractoriness (PTR) occurs. Abnormal bleeding in patients with liver cancer is closely related to platelets level. Therefore, it is very important to explore the regulation of platelets by Chinese and western medicine in the treatment of PTR in patients with liver cancer. In this paper, platelet generation, PTR mechanism in patients with liver cancer, regulation and intervention measures of Chinese and western medicine are briefly reviewed, so as to provide reference for the clinical treatment of PTR in patients with liver cancer and broaden treatment ideas.
农耀斌1 黄鸿娜2 黄晶晶3 董芷辛4 宋文选1 肖熹煜1 杜沅沁1. 中西医干预肝癌患者血小板无效输注的研究进展[J]. 中国医药导报, 2023, 20(3): 41-44.
NONG Yaobin1 HUANG Hongna2 HUANG Jingjing3 DONG Zhixin4 SONG Wenxuan1 XIAO Xiyu1 DU Yuanqin1. Research progress of Chinese and western medicine intervention on platelet transfusion refractoriness in patients with liver cancer. 中国医药导报, 2023, 20(3): 41-44.
[1] Zhou M，Wang H，Zeng X，et al. Mortality，morbidity，and risk factors in China and its provinces，1990—2017：a systematic analysis for the Global Burden of Disease Study 2017 [J]. Lancet，2019，394（10204）：1145-1158.
[2] Giannini S，Lee-Sundlov MM，Rivadeneyra L，et al. β4GALT1 controls β1 integrin function to govern thrombopoiesis and hematopoietic stem cell homeostasis [J]. Nat Commun，2020， 11（1）：356.
[3] 傅毅振，徐立.肝细胞癌综合治疗进展[J].临床肝胆病杂志，2020，36（10）：2179-2183.
[4] Potts KS，Farley A，Dawson CA，et al. Membrane budding is a major mechanism of in vivo platelet biogenesis [J]. J Exp Med，2020，217（9）：e20191206.
[5] Wang H，He J，Xu C，et al. Decoding Human Megakaryocyte Development [J]. Cell Stem Cell，2021，28（3）：535-549.e8.
[6] Handtke S，Steil L，Palankar R，et al. Role of Platelet Size Revisited-Function and Protein Composition of Large and Small Platelets [J]. Thromb Haemost，2019，119（3）：407-420.
[7] Harrison P，Goodall AH.“Message in the platelet”——more than just vestigial mRNA！[J]. Platelets，2008，19（6）：395-404.
[8] Hamad MA，Schanze N，Schommer N，et al. Reticulated Platelets-Which Functions Have Been Established by In Vivo and In Vitro Data？[J]. Cells，2021，10（5）：1172.
[9] Qu M，Zou X，Fang F，et al. Platelet-derived microparticles enhance megakaryocyte differentiation and platelet generation via miR-1915-3p [J]. Nat Commun，2020，11（1）：4964.
[10] Chen S，Qi Y，Wang S，et al. Melatonin enhances thrombopoiesis through ERK1/2 and Akt activation orchestrated by dual adaptor for phosphotyrosine and 3-phosphoinositides [J]. J Pineal Res，2020，68（3）：e12637.
[11] Liu C，Huang B，Wang H，et al. The heterogeneity of megakaryocytes and platelets and implications for exvivo platelet generation [J]. Stem Cells Transl Med，2021，10（12）：1614- 1620.
[12] Meinke S，Karlstr?觟m C，H?觟glund P. Complement as an Immune Barrier in Platelet Transfusion Refractoriness [J]. Transfus Med Rev，2019，33（4）：231-235.
[13] Refaai MA，Carter J，Henrichs KF，et al. Alterations of platelet function and clot formation kinetics after in vitro exposure to anti-A and -B [J]. Transfusion，2013，53（2）：382-393.
[14] 晏丽，李萍，谢小双.HPA基因多态性对肝病患者血小板输注疗效的评估价值[J].临床血液学杂志，2022，35（6）：447-450.
[15] Kuijpers MJ，de Witt S，Nergiz-Unal R，et al. Supporting roles of platelet thrombospondin-1 and CD36 in thrombus formation on collagen [J]. Arterioscler Thromb Vasc Biol，2014，34（6）：1187-1192.
[16] Michael JV，Wurtzel JGT，Mao GF，et al. Platelet microparticles infiltrating solid tumors transfer miRNAs that suppress tumor growth [J]. Blood，2017，130（5）：567-580.
[17] Nagelkerke SQ，Porcelijn L，Geissler J，et al. The association and functional relevance of genetic variation in low- to-medium-affinity Fc-gamma receptors with clinical platelet transfusion refractoriness [J]. J Thromb Haemost，2020，18（8）：2047-2053.
[18] Solves P，Sanz J，Freiria C，et al. Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation [J]. Ann Hematol，2018，97（1）：161-167.
[19] Tanoue S，Konuma T，Kato S，et al. Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation for Adults：Risk Factors and Clinical Outcomes [J]. Biol Blood Marrow Transplant，2018，24（9）：1873-1880.
[20] 何作萍，罗佩芳，杨斌.血小板输注疗效的影响因素分析[J].中国临床新医学，2020，13（8）：805-808.
[21] Qiao J，Wu Y，Liu Y，et al. Busulfan Triggers Intrinsic Mitochondrial-Dependent Platelet Apoptosis Independent of Platelet Activation [J]. Biol Blood Marrow Transplant，2016， 22（9）：1565-1572.
[22] 姚勇，张欢欢，孙振超，等.单采血小板保存期内活化状态及相关功能和代谢指标检测及分析[J].中国输血杂志，2021，34（2）：120-123.
[23] 满志然，张勇，王永志.血液病患者血小板输注效果分析[J].北京医学，2021，43（10）：980-983.
[24] Slichter SJ，Bailey SL，Gettinger I，et al. Pathogen reduction with amotosalen/UVA reduces platelet refractoriness in a dog platelet transfusion model [J]. Vox Sang，2019，114（6）：595-604.
[25] Tanaka Y，Matsumoto I，Saito D，et al. Utility of Partial Splenic Embolization Prior to Lung Resection in Patients Demonstrating Platelet Transfusion Refractoriness Due to Hypersplenism [J]. Kyobu Geka，2017，70（13）：1063-1067.
[26] Oh SE，Seo JE，An JY，et al. Prognostic Impact of Increased Perioperative Platelet Count in Gastric Cancer Patients [J]. J Surg Res，2019，242：296-303.
[27] Kickler T，Braine HG，Piantadosi S，et al. A randomized，placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients [J]. Blood，1990， 75（1）：313-316.
[28] 许飞，贺晨峰，曹锁春，等.常州地区单采血小板捐献者HLA抗原分布情况[J].临床血液学杂志，2018，31（2）：294-296.
[29] Tannous E，Lipman S，Tonna A，et al. Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia [J]. Antimicrob Agents Chemother，2020，64（8）：e02571-19.
[30] 周迪，周永明.肿瘤化疗相关性血小板减少症的中医病机特点及治疗对策[J].上海中医药杂志，2022，56（2）：6-9.
[31] 张晶，罗昌国，王济国，等.升板汤治疗化疗所致血小板减少症的临床研究[J].辽宁中医杂志，2021，48（12）：133-136.
[32] 徐昊，黄小平，张伟，等.黄芪和当归的主要活性成分配伍对骨髓抑制小鼠造血功能的影响[J].中国药理学通报，2019，35（5）：707-713.
[33] 薛露，王海丽，单鸣秋，等.茜草炭不同提取物对子言出血模型大鼠影响的比较研究[J].辽宁中医杂志，2017， 44（3）：640-643.
[34] 高雅婷，张永军.基于Caspase途径探讨花生红衣对化疗后血小板减少症小鼠的影响[J].新中医，2020，52（19）：1-3.
京公网安备 11010502046598号